vic3308

ά¶àÀûÑÇÀÏÆ·ÅÆvic3308(Öйú)¹É·ÝÓÐÏÞ¹«Ë¾

¹ÉƱ´úÂë

SSE: 603127
HKEX: 06127
ά¶àÀûÑÇÀÏÆ·ÅÆvic3308(Öйú)¹É·ÝÓÐÏÞ¹«Ë¾

ÇëÊäÈëËÑË÷Òªº¦´Ê£¡

ÕÑÑÜÐÂÒ©³öϯµÚ64½ìÃÀ¹úSOTÄê»á²¢×÷ÕªÒª·ÖÏí

2025-01-22

ά¶àÀûÑÇÀÏÆ·ÅÆvic3308(Öйú)¹É·ÝÓÐÏÞ¹«Ë¾

µÚ64½ìÃÀ¹ú¶¾Àíѧ»á£¨SOT£©Äê»á½«ÓÚÃÀ¹ú¶«²¿Ê±¼ä2025Äê3ÔÂ16ÈÕ-20ÈÕÔÚÃÀ¹ú°ÂÀ¼¶à¾ÙÐС£¡£¡£ ¡£¡£» £»£»£»£»£»£»£¾Û»áΪÆÚÎåÌ죬£¬£¬£¬£¬£¬£¬ÎüÒýÁË500Óàλ¶¾Àíѧר¼Ò¾Û½¹Ç°ÑØ»úÖÆ¡¢Î£º¦ÆÀ¹ÀµÈÒéÌâ¾ÙÐÐÉîÈë×êÑУ¬£¬£¬£¬£¬£¬£¬³¬ 2000 ·ÝÌåÍâ¡¢ÌåÄÚ¶¾ÀíѧЧ¹ûº£±¨²ÎÕ¹£¬£¬£¬£¬£¬£¬£¬Ôö½øÑ§Êõ½»Á÷¡£¡£¡£ ¡£¡£» £»£»£»£»£»£»£¾Û»á»ã¾ÛÈ«Çò 50 ¶à¹ú¡¢³¬8000Ãû¿ÆÑÐÖ°Ô±¡¢´ÓÒµÕß¼°ÆóÒµÖ÷¸É£¬£¬£¬£¬£¬£¬£¬´î½¨¿çÇøÓòÏàÖúƽ̨£¬£¬£¬£¬£¬£¬£¬Íƶ¯ÐÐÒµÉú³¤¡£¡£¡£ ¡£¡£

ÕÑÑÜÐÂÒ©Ê×ϯ¿ÆÑ§¼ÒÒ¦´óÁÖ²©Ê¿¡¢ÕÑÑÜÐÂÒ©¸±×ܲüæÁªÏ¯Ê×ϯÊÖÒÕ¹ÙÕÅÓÀ±ó²©Ê¿½«³öϯ´Ë´Î¾Û»á¡£¡£¡£ ¡£¡£½ìʱ£¬£¬£¬£¬£¬£¬£¬ÕÑÑÜÐÂÒ©½«¾ÙÐÐ7¸öÖ÷ÌâµÄ±Ú±¨·ÖÏíÓë½²ÑÝ£¬£¬£¬£¬£¬£¬£¬¼ÓÈëС×é¾Û»áµÄÖ÷Ìâ·ÖÏí¡£¡£¡£ ¡£¡£ÕÑÑÜÐÂÒ© JOINN/BiomereÉèÁ¢ÁËչ̨£¨Õ¹Î»ºÅ#1351£©£¬£¬£¬£¬£¬£¬£¬ÏêϸÏÈÈݹ«Ë¾ÔÚÒ©ÎïÈ«ÉúÃüÖÜÆÚÖеĽâ¾ö¼Æ»®£¬£¬£¬£¬£¬£¬£¬½Ó´ýÒµ½çͬÈÊǰÀ´½»Á÷Ǣ̸¡£¡£¡£ ¡£¡£


SOT, JOINN, BIOMERE


| רÌⱨ¸æ £¨Session Presentation£©

±¨¸æÖ÷Ì⣨Session Title£©£ºAdvanced Capabilities for Ocular Drug Development Using NHP Models£¨·ÇÈËÁ鳤ÀදÎïÓÃÓÚÑÛ¿ÆÐÂÒ©Ñз¢£©

±¨¸æÊ±¼ä£¨Date & Time£©£º2024Äê3ÔÂ17ÈÕ 13:45-14:45£¨ÃÀ¹ú¶«²¿Ê±¼ä£©March 17th (Mon), 1:45-2:45pm

±¨¸æËùÔÚ£¨Location£©£º³ÈÏØ¾Û»áÖÐÐÄ W208B¾Û»áÊÒ£¨West Concourse of the Orange County Convention Center£¬£¬£¬£¬£¬£¬£¬Room W208B£©

Ö÷½²ÈË£¨Presenting Author£©£ºÐ»ÍòÀ¤²©Ê¿£¬£¬£¬£¬£¬£¬£¬ÕÑÑÜ£¨ËÕÖÝ£©ÑÛ¿Æ×ܼà


| Ö°ÒµÍýÏë½²×ù £¨AACT Career Workshop£©

±¨¸æÊ±¼ä£¨Date & Time£©£º2024Äê3ÔÂ17ÈÕ 17:00-18:00£¨ÃÀ¹ú¶«²¿Ê±¼ä£©March 17th (Mon), 5:00-6:00 pm

±¨¸æËùÔÚ£¨Location£©£º¿­ÔÃÂùÝεÂÃ×¶ûÊ®ºÅÌü£¨Windermere Ballroom X, Hyatt Regency£©

Ö÷½²ÈË£¨Presenting Author£©£ºÕÅÓÀ±ó²©Ê¿£¬£¬£¬£¬£¬£¬£¬¸±×ܲã¨VP£©¼æÁªÏ¯Ê×ϯÊÖÒÕ¹Ù£¨CO-CTO£©

Ö÷½²È˼ò½é£¨Brief£©£º½áÒµÓÚÖйúũҵ´óѧ»ñÊÞҽѧרҵѧλ,ºóÓÚÃÀ¹ú¶í¿ËÀ­ºÉÂíÖÝÁ¢´óѧ»ñµÃ¶¾Àíѧ²©Ê¿Ñ§Î»¡£¡£¡£ ¡£¡£ËûÔÚFDAµÄ¹ú¼Ò¶¾ÀíѧÑо¿ÖÐÐÄNCTRÍê³É²©Ê¿ºóÑо¿£¬£¬£¬£¬£¬£¬£¬ËæºóÕýʽÈëÖ°FDA×÷Ϊ¶¾ÀíѧÏîÄ¿ÈÏÕæÈ˽¨Éè²¢Ïòµ¼FDAµÄÄÉÃ×¶¾ÀíѧʵÑéÊÒ¼ÓÈëÁËÊýÏîÐÂÒ©ºÍҩеÏà¹ØÏîÄ¿Ñо¿¼°Çå¾²ÐÔÆÀ¼Û¡£¡£¡£ ¡£¡£ÔÚ15ÄêFDAÖ°ÒµÉúÑÄÖУ¬£¬£¬£¬£¬£¬£¬ÆäÔÚÁ¢ÒìÒ©ÉóÆÀÖÐÐÄ×÷Ϊ·ÇÁÙ´²¸ß¼¶ÉóÆÀר¼ÒÈÏÕæÁËÊý°Ù¸öÐÂÒ©¿ª·¢µÄINDºÍÊýÊ®¿îÐÂÒ©µÄÉÏÊÐÉóÅúÊÂÇ飬£¬£¬£¬£¬£¬£¬²¢¼ÓÈë¶àÏîFDAÐÂÒ©ÆÀ¼ÛÖ¸ÄÏµÄÆð²ÝÖÆ¶©µÈ¡£¡£¡£ ¡£¡£Òò´ËÕŲ©Ê¿ÔøÈÙ»ñFDAÓÅÒìÇàÄê¿ÆÑ§¼Ò½±ºÍFDAÓÅÒìЧÀͽ±¡£¡£¡£ ¡£¡£ËûÔøÈÎÖ°ÓÚºÉÀ¼Ó¢ÌØÍþ¹ú¼ÊÓÐÏÞ¹«Ë¾(ÏÖÁ¥Êô Merck·Ö²¿)ÈÏÕæ²úÆ·µÄÊг¡ÊÖÒÕÖ§³Ö¡£¡£¡£ ¡£¡£ÆäÔøÔÚÃÀ¹ú¶¾Àíѧ»áµÄ±±ÃÀ»ªÈ˶¾Àíѧ»áµ£µ±»á³¤ºÍÄÉÃ×¶¾Àíѧ»á·Ö»áµ£µ±×¨ÒµÎ¯Ô±»áÀíÊ¡£¡£¡£ ¡£¡£



| ±Ú±¨Õ¹Ê¾£¨Poster£©¿ÉÒÔÔÚչλ1351Ãâ·Ñ»ñÈ¡±Ú±¨ÄÚÈÝ

01

±Ú±¨Õ¹Ê¾ºÅ£¨Abstract Number/Poster Board number£©£º4254/Q770

±Ú±¨Ö÷Ì⣨Abstract Title£©£ºAnalysis of Toxicity Characteristics of GLP-1 Receptor Agonists in Non-clinical Safety Evaluation£¨GLP-1ÊÜÌ弤¶¯¼ÁÔÚ·ÇÁÙ´²Çå¾²ÐÔÆÀ¼ÛÖе;ÐÔÌØÕ÷ÆÊÎö£©

±Ú±¨¼ò½é£¨Introduction£©£ºÒȸßѪÌÇËØÑùëÄ-1ÊÜÌ弤¶¯¼Á£¨GLP-1RA£©ÊÇÒ»ÀàеĽµÌÇÒ©Î£¬£¬£¬£¬£¬£¬¿ÉÒÔͨ¹ý¼¤»îGLP-1ÊÜÌåÀ´½µµÍѪÌǺÍ×ÊÖú¼õ·Ê¡£¡£¡£ ¡£¡£GLP-1RA»¹¾ßÓпØÖÆÌåÖØ¡¢¸ÄÉÆ·Ç¾Æ¾«ÐÔÖ¬·¾¸ÎµÈ¶àÖÖÁÙ´²Òæ´¦£¬£¬£¬£¬£¬£¬£¬ÕýÖð½¥³ÉΪÖÎÁÆÌÇÄò²¡µÄÖ÷Òª´¦·½Ò©¡£¡£¡£ ¡£¡£±¾Ñо¿ÒÔ×¢Éä¼ÁΪÖ÷µÄGLP-1RA¶¾ÐÔÑо¿Ð§¹û¾ÙÐÐ×ܽᣬ£¬£¬£¬£¬£¬£¬²¢ÍŽáÒÑÉÏÊÐͬÀà²úÆ·µÄ¶¾ÐÔÌØµã£¬£¬£¬£¬£¬£¬£¬Îª¸ÃÀà²úÆ·µÄ·ÇÁÙ´²Çå¾²ÐÔÆÀ¼ÛºÍ¶¾ÐÔÆÊÎöÌṩ²Î¿¼ÒÀ¾Ý¡£¡£¡£ ¡£¡£

±Ú±¨ÏÈÈÝʱ¼ä£¨Date & Time£©£º2025Äê3ÔÂ18ÈÕ 13:45-16:15£¨ÃÀ¹ú¶«²¿Ê±¼ä£©March 18th (Mon), 1:45-4:15 pm

±Ú±¨°å¿é£¨Session Title£©£ºSafety Assessment£ºNon-pharmaceutical

±Ú±¨Ö÷½²ÈË£¨Presenting Author£©£ºÂí½ðÁá Jinling Ma


02

±Ú±¨Õ¹Ê¾ºÅ£¨Abstract Number/Poster Board number£©£º4166/N676

±Ú±¨Ö÷Ì⣨Abstract Title£©£ºIn vivo Imaging and Quantification of Retinal and Choroidal Vasculature in Cynomolgus Monkeys using Optical Coherence Tomography Angiography£¨¹âѧÏà¹Ø¶Ï²ãɨÃèѪ¹ÜÔìÓ°ÔÚʳзºïÊÓÍøÄ¤ºÍÂöÂçĤѪ¹ÜµÄÌåÄÚ³ÉÏñºÍ¶¨Á¿Ñо¿£©

±Ú±¨¼ò½é£¨Introduction£©£º¹âѧÏà¹Ø¶Ï²ãѪ¹ÜÔìÓ°£¨OCTA£©ÊÇÒ»ÖÖеÄÎÞ´´ÊÖÒÕ£¬£¬£¬£¬£¬£¬£¬ÓÃÓÚ¿ÉÊÓ»¯ÊÓÍøÄ¤ºÍÂöÂçĤ΢Ѫ¹Üϵͳ¡£¡£¡£ ¡£¡£·ÇÈËÁ鳤ÀදÎïÓÉÓÚÆäÓëÈËÑÛµÄÆÊ½âºÍÒÅ´«ÏàËÆÐÔ¶ø±»ÆÕ±éÓ¦ÓÃÓÚÁÙ´²Ç°ÑÛ¿ÆÑо¿¡£¡£¡£ ¡£¡£±¾Ñо¿µÄÄ¿µÄÊDZíÕ÷NHPµÄOCTAÌØÕ÷£¬£¬£¬£¬£¬£¬£¬²¢½¨Éè±ê×¼»¯µÄÒªÁìÀ´ÆÀ¹ÀNHPµÄÊÓÍøÄ¤Ñª¹Ü¸´ºÏÎ£¬£¬£¬£¬£¬£¬ÓÃÓÚÁÙ´²Ç°ÑÛ¿ÆÑо¿¡£¡£¡£ ¡£¡£

±Ú±¨ÏÈÈÝʱ¼ä£¨Date & Time£©£º2025Äê3ÔÂ18ÈÕ 13:45-16:15£¨ÃÀ¹ú¶«²¿Ê±¼ä£©March 18th (Mon), 1:45-4:15 pm

±Ú±¨°å¿é£¨Session Title£©£ºOcular Toxicology

±Ú±¨Ö÷½²ÈË£¨Presenting Author£©£ºÐ»ÍòÀ¤ Wankun Xie

 

03

±Ú±¨Õ¹Ê¾ºÅ£¨Abstract Number/Poster Board number£©£º3670/A130

±Ú±¨Ö÷Ì⣨Abstract Title£©£ºPharmacodynamic Effect and Toxicity Study of Multi-specific Antibodies in a Humanized Mouse Model with Tumor-Bearing£¨¶àÌØÒìÐÔ¿¹ÌåÔÚÈËÔ´»¯Ð¡ÊóºÉÁöÄ£×ÓÖеÄҩЧѧЧӦ¼°¶¾ÐÔÑо¿£©

±Ú±¨¼ò½é£¨Introduction£©£ºTϸ°û½ÓºÏÎï£¨Ë«ÌØÒìÐÔ¿¹Ì壩¼ÈÄÜÓëÖ×Áöϸ°ûÍŽᣬ£¬£¬£¬£¬£¬£¬Ò²ÄÜÓëÃâÒßϸ°ûÈçTϸ°ûÍŽᣬ£¬£¬£¬£¬£¬£¬Í¨¹ý˫͎áÖ¸µ¼ÃâÒßϸ°ûɱËÀÖ×Áöϸ°û¡£¡£¡£ ¡£¡£È»¶ø£¬£¬£¬£¬£¬£¬£¬Ë«ÌØÒìÐÔ¿¹ÌåºÜÈÝÒ×½øÈëÒ»ÖÖ±»ºÄ¾¡µÄ״̬£¬£¬£¬£¬£¬£¬£¬µ¼Ö¼¤»îµÄTϸ°ûÓÉÓÚȱ·¦¹²´Ì¼¤·Ö×Ó¶øÔÚÓ¦Óú󲻾ñäµÃÎÞ·´Ó¦¡£¡£¡£ ¡£¡£» £»£»£»£»£»£»£»ùÓÚÒÔÉÏÊӲ죬£¬£¬£¬£¬£¬£¬ÎÒÃÇÖÆ±¸ÁËÌí¼Ó¹²´Ì¼¤·Ö×ÓµÄÈýÌØÒìÐÔ¿¹Ì壬£¬£¬£¬£¬£¬£¬×èÖ¹ÁËTϸ°û±»¼òµ¥Ðźż¤»î¶øËðʧÄÜÁ¦£¬£¬£¬£¬£¬£¬£¬ÓÐÍûÌá¸ßtϸ°û¶ÔÖ×Áöϸ°ûµÄɱÉËЧ¹û¡£¡£¡£ ¡£¡£±¾Ñо¿ÆÀ¼ÛÁËCD3/CD20/CD28¿¹ÌåºÍBlinatumomabÀàËÆÎïµ¥¿Ë¡¿¹Ìå¶ÔRajiÔØÁöNPGÈËÔìѪ¸Éϸ°û£¨HSC£©ÖØÐÞСÊóÄ£×ӵĿ¹°©Ð§¹ûºÍDZÔÚ¶¾ÐÔ£¬£¬£¬£¬£¬£¬£¬ÒÔ¼°ËüÃÇÔÚÌåÍâ¶ÔÈËÍâÖÜѪµ¥ºËϸ°û£¨PBMCs£©»î»¯µÄÓ°Ïì¡£¡£¡£ ¡£¡£

±Ú±¨ÏÈÈÝʱ¼ä£¨Date & Time£©£º2025Äê3ÔÂ18ÈÕ 13:45-16:15£¨ÃÀ¹ú¶«²¿Ê±¼ä£©March 18th (Mon), 1:45-4:15 pm

±Ú±¨°å¿é£¨Session Title£©£ºImmunotoxicity I

±Ú±¨Ö÷½²ÈË£¨Presenting Author£©£ºLi Sun

 

04

±Ú±¨Õ¹Ê¾ºÅ£¨Abstract Number/Poster Board number£©£º3644/A102

±Ú±¨Ö÷Ì⣨Abstract Title£©£ºComparison of Cytokine Release Syndrome induced by Chimeric Antigen Receptor T Cells in Humanized NOG-EXL mice and NOG mice£¨Ç¶ºÏ¿¹Ô­ÊÜÌåTϸ°ûÓÕµ¼ÈËÔ´»¯NOG-EXLСÊóºÍNOGСÊóϸ°ûÒò×ÓÊÍ·Å×ÛºÏÕ÷µÄ½ÏÁ¿£©

±Ú±¨¼ò½é£¨Introduction£©£ºTϸ°û½éµ¼µÄ°©Ö¢ÃâÒßÁÆ·¨£¬£¬£¬£¬£¬£¬£¬°üÀ¨Ç¶ºÏ¿¹Ô­ÊÜÌ壨CAR£©Tϸ°ûÁÆ·¨ºÍÕÙļϸ°û¶¾ÐÔTÁܰÍϸ°û£¨CTLs£©µ½°©Ï¸°ûµÄË«ÌØÒìÐÔ¿¹Ì壬£¬£¬£¬£¬£¬£¬Ö±½Óʶ±ð°©Ï¸°ûÍâò¿¹Ô­£¬£¬£¬£¬£¬£¬£¬¶ø²»ÊÜMHCÏÞÖÆ¡£¡£¡£ ¡£¡£Ö»¹ÜÔÚÁÙ´²Ó¦ÓÃÖжԶñÐÔÖ×Áö¾ßÓÐÏÔÖøµÄÁÆÐ§£¬£¬£¬£¬£¬£¬£¬µ«CAR - Tϸ°ûÁÆ·¨¾­³£°éÓÐÑÏÖØµÄϸ°ûÒò×ÓÊÍ·Å×ÛºÏÕ÷£¨CRS£©£¬£¬£¬£¬£¬£¬£¬ÕâÊÇCAR - Tϸ°ûÃâÒßÁÆ·¨µÄÈõµãÖ®Ò»¡£¡£¡£ ¡£¡£ÎÒÃÇ֮ǰ±¨µÀÁËÊä×¢µÄCAR-Tϸ°ûÔÚºÉÁöNOGСÊóÖеĻºÍÖ×Áö¸ººÉµÄÏûÍË£¬£¬£¬£¬£¬£¬£¬ÆäÖÐѪÇåÖÐÈËÀàϸ°ûÒò×ÓµÄÊÍ·ÅÊÇÐþÃîµÄ¡£¡£¡£ ¡£¡£¿£¿£¿£¿£¿£¿£¿£Ë¼Á¿µ½¶àÖÖÈËÀàÃâÒßϸ°û¼ÓÈëÁËCRS£¬£¬£¬£¬£¬£¬£¬Òò´ËÎÒÃÇÆÀ¹ÀÁËÈËÀàÔìѪ¸Éϸ°û£¨HSC£©ÒÆÖ²ºÍÖ×ÁöÖ²ÈëNOG-EXLСÊóµÄCRS¡£¡£¡£ ¡£¡£ÔÚÈËÔ´»¯NOG-EXLÄ£×ÓÖУ¬£¬£¬£¬£¬£¬£¬ÎÒÃÇ·¢Ã÷СÊóÍâÖÜѪÖÐ×¢ÉäCAR-Tϸ°ûºó£¬£¬£¬£¬£¬£¬£¬ÈËTϸ°û¡¢Bϸ°ûºÍ¹ÇËèϸ°ûÀ©Ôö£¬£¬£¬£¬£¬£¬£¬ÈËϸ°ûÒò×ÓˮƽÉý¸ß¡£¡£¡£ ¡£¡£

±Ú±¨ÏÈÈÝʱ¼ä£¨Date & Time£©£º2025Äê3ÔÂ18ÈÕ 13:45-16:15£¨ÃÀ¹ú¶«²¿Ê±¼ä£©March 18th (Mon), 1:45-4:15 pm

±Ú±¨°å¿é£¨Session Title£©£ºImmunotoxicity I

±Ú±¨Ö÷½²ÈË£¨Presenting Author£©£ºYang Cao


05

±Ú±¨Õ¹Ê¾ºÅ£¨Abstract Number/Poster Board number£©£º3641/A101

±Ú±¨Ö÷Ì⣨Abstract Title£©£ºTherapeutic effects of anti-TNF-¦Á monoclonal antibody on cytokine release induced by CAR-T cells targeting CD22£¨¿¹TNF-¦Áµ¥¿Ë¡¿¹Ìå¶Ô°ÐÏòCD22µÄCAR-Tϸ°ûÓÕµ¼µÄϸ°ûÒò×ÓÊͷŵÄÖÎÁÆ×÷Óã©

±Ú±¨¼ò½é£¨Introduction£©£ºÖ»¹Üϸ°ûÒò×ÓÊÍ·Å×ÛºÏÕ÷£¨CRS£©ÊÇCAR-Tϸ°ûÖÎÁÆ×î³£¼ûµÄÁÙ´²¸±×÷Ó㬣¬£¬£¬£¬£¬£¬µ«ÔÚʹÓÃÃâÒßȱÏÝСÊóÔØÁöÄ£×ÓµÄÁÙ´²Ç°Ñо¿ÖкÜÉÙ¼ûµ½¡£¡£¡£ ¡£¡£µ±ÎÒÃÇÔÚNOG-RajiСÊóÄ£×ÓÖÐÆÀ¹Àcd22ÌØÒìÐÔCAR-Tϸ°û²úÆ·µÄÓÐÓÃÐÔºÍÇå¾²ÐÔʱ£¬£¬£¬£¬£¬£¬£¬·¢Ã÷ÁËCAR-Tϸ°ûÏà¹ØµÄ¶¾ÐÔ·´Ó¦£¬£¬£¬£¬£¬£¬£¬°üÀ¨¶ÌÔݵÄÌåÖØ¼õÇáºÍ¶¯ÎïéæÃü¡£¡£¡£ ¡£¡£ÔÚËæºóµÄÊý¾ÝÆÊÎöÖУ¬£¬£¬£¬£¬£¬£¬Òì³£Éý¸ßµÄTNF-¦Áˮƽ±»ÒÔΪÓëСÊóµÄÕâÖÖ¶¾ÐÔ·´Ó¦ÓйØ¡£¡£¡£ ¡£¡£¿£¿£¿£¿£¿£¿£¿£¿¹Ö×Áö»µËÀÒò×Ó-¦Áµ¥¿Ë¡¿¹Ì壨°¢´ïľµ¥¿¹£©ÖÎÁÆ¿ÉÔÚ²»Ó°ÏìCAR-Tϸ°û¿¹Ö×Áö×÷ÓõÄÇéÐÎÏÂÞ׿¹Ð¡ÊóÌåÖØ¼õÇá²¢½µµÍéæÃüÂÊ¡£¡£¡£ ¡£¡£vic3308Ñо¿Ð§¹ûÅú×¢£¬£¬£¬£¬£¬£¬£¬ÍâÖÜѪTNF-¦ÁˮƽÉý¸ß¿ÉÄÜÊÇÕâÖÖCAR-Tϸ°û²úƷδÀ´µÄÁÙ´²¶¾ÐÔ±ê¼Ç£¬£¬£¬£¬£¬£¬£¬TNF-¦ÁÖкÍÁÆ·¨¿ÉÄÜÊÇÔ¤·ÀºÍÖÎÁÆÇ±ÔÚÁÙ´²CRSµÄ¿ÉÐмƻ®¡£¡£¡£ ¡£¡£

±Ú±¨ÏÈÈÝʱ¼ä£¨Date & Time£©£º2025Äê3ÔÂ18ÈÕ 13:45-16:15£¨ÃÀ¹ú¶«²¿Ê±¼ä£©March 18th (Mon), 1:45-4:15 pm

±Ú±¨°å¿é£¨Session Title£©£ºImmunotoxicity I

±Ú±¨Ö÷½²ÈË£¨Presenting Author£©£ºYang Chen


06

±Ú±¨Õ¹Ê¾ºÅ£¨Abstract Number/Poster Board number£©£º3668-A128

±Ú±¨Ö÷Ì⣨Abstract Title£©£ºImmunogenicity Concerns in Preclinical Safety Evaluation of Biologics in Non-human Primates£¨ÉúÎïÖÆ¼ÁÁÙ´²Ç°Çå¾²ÐÔÆÀ¼ÛÖеÄÃâÒßÔ­ÐÔÎÊÌ⡪¡ª·ÇÈËÀàÁ鳤Àࣩ

±Ú±¨¼ò½é£¨Introduction£©£º

Õë¶Ô¿ÉÈÜÉúÎï°ÐµãµÄµ¥¿Ë¡¿¹Ìå¡¢Ë«ÌØÒìÐÔ¿¹ÌåºÍÈÚºÏÂѰ׵ÈÉúÎïÒ©ÎK´óµØ¸ÄÉÆÁËÄÑÖÎÐÔ»òÓÐÊý²¡µÄҽѧÖÎÁÆ¡£¡£¡£ ¡£¡£·ÇÈËÁ鳤ÀදÎNon-human primate, NHPs£©¾ßÓÐÓÅÒìµÄҩЧѧ¡¢¶¾ÀíѧӰÏìºÍÐÄÀíЧӦչÍû¼ÛÖµ£¬£¬£¬£¬£¬£¬£¬Òѱ»Ö¤ÊµÊÇÉúÎïÖÆ¼ÁÁÙ´²Ç°Çå¾²ÐÔÆÀ¹ÀµÄÖ÷Òª¶¯ÎïÎïÖÖ¡£¡£¡£ ¡£¡£È»¶ø£¬£¬£¬£¬£¬£¬£¬ÃâÒßÔ­ÐÔÈÔÊÇ·ÇÈËÁ鳤ÀදÎï¾ÙÐÐÉúÎïÖÆ¼ÁÇå¾²ÐÔÆÀ¹ÀµÄÒ»¸öÖ÷ÒªÎÊÌ⣬£¬£¬£¬£¬£¬£¬¿ÉÄÜ»áÓ°Ïì¶ÔÈËÀ಻Á¼·´Ó¦µÄÕ¹Íû¼ÛÖµ¡£¡£¡£ ¡£¡£±¾Ñо¿Ö¼ÔÚÌá³öÉúÎïÖÆÆ·ÁÙ´²Ç°Çå¾²ÐÔÆÀ¼ÛÑо¿ÖÐÃâÒßÔ­ÐÔʶ±ðºÍ¸ÉÔ¤»úÖÆµÄÏêϸ²ÎÊý»òÒªÁì¡£¡£¡£ ¡£¡£

±Ú±¨ÏÈÈÝʱ¼ä£¨Date & Time£©£º2025Äê3ÔÂ18ÈÕ 13:45-16:15£¨ÃÀ¹ú¶«²¿Ê±¼ä£©March 18th (Mon), 1:45-4:15 pm

±Ú±¨°å¿é£¨Session Title£©£ºImmunotoxicity I

±Ú±¨Ö÷½²ÈË£¨Presenting Author£©£ºÕÅÓÀ±óYongbin Zhang

 

07

±Ú±¨Õ¹Ê¾ºÅ£¨Abstract Number/Poster Board number£©£º3612-P767

±Ú±¨Ö÷Ì⣨Abstract Title£©£ºImmunogenicity Concerns in Preclinical Safety Evaluation of Biologics in Sprague-Dawley Rats£¨ÉúÎïÖÆ¼ÁÁÙ´²Ç°Çå¾²ÐÔÆÀ¼ÛÖеÄÃâÒßÔ­ÐÔÎÊÌ⡪¡ªSD´óÊó£©

±Ú±¨¼ò½é£¨Introduction£©£º

½üÄêÀ´£¬£¬£¬£¬£¬£¬£¬µ¥¿Ë¡¿¹Ìå¡¢Ë«ÌØÒìÐÔ¿¹Ìå¡¢ÈÚºÏÂѰ׵ÈÉúÎïÖÆ¼ÁµÄÉú³¤Îª¸ÄÉÆÐÄѪ¹Üϵͳ¡¢ºôÎüϵͳ¡¢°©Ö¢¡¢ÔìѪϵͳ¼²²¡¡¢×ÔÉíÃâÒßÐÔ¼²²¡µÈÖÖÖÖ¼²²¡µÄҽѧÖÎÁÆ×ö³öÁËÖØ´óТ˳¡£¡£¡£ ¡£¡£ÓÃSD´óÊó¾ÙÐж¯ÎïʵÑéÊÇÉúÎïÖÆ¼ÁÇå¾²ÐÔÆÀ¼ÛµÄ³£ÓúÍÓмÛÖµµÄ¹¤¾ß¡£¡£¡£ ¡£¡£È»¶ø£¬£¬£¬£¬£¬£¬£¬µ±ÔÚ´óÊóÖоÙÐÐÉúÎïÖÆ¼ÁµÄÇå¾²ÐÔÆÀ¹ÀÑо¿Ê±£¬£¬£¬£¬£¬£¬£¬ÃâÒßÔ­ÐÔÈÔÈ»ÊÇÒ»¸öÎÊÌâºÍ/»òÌôÕ½£¬£¬£¬£¬£¬£¬£¬Õâ¿ÉÄÜ»áË𺦶ÔÈËÀ಻Á¼·´Ó¦µÄÕ¹ÍûÖµ¡£¡£¡£ ¡£¡£È»¶ø£¬£¬£¬£¬£¬£¬£¬´óÊó¶ÔÈËÌåҩЧѧºÍ¶¾ÀíѧӰÏìȷʵÓкܺõÄÕ¹Íû¼ÛÖµ¡£¡£¡£ ¡£¡£±¾×ÛÊöµÄÄ¿µÄÊÇÆÀ¹ÀÉúÎïÖÆÆ·¶¾ÐÔÑо¿µÄÁÙ´²Ç°Êý¾Ý£¬£¬£¬£¬£¬£¬£¬ÒÔÑо¿ÉúÎïÖÆÆ·µÄÃâÒßÔ­ÐÔ¡£¡£¡£ ¡£¡£

±Ú±¨ÏÈÈÝʱ¼ä£¨Date & time£©£º2025Äê3ÔÂ17ÈÕ 09:15-11:45£¨ÃÀ¹ú¶«²¿Ê±¼ä£©March 17th (Mon), 9:15-11:45 am

±Ú±¨°å¿é£¨Session Title£©£ºImmunotoxicity I

±Ú±¨Ö÷½²ÈË£¨Presenting Author£©£ºÕÅÇÕÃ÷Luke Zhang






ά¶àÀûÑÇÀÏÆ·ÅÆvic3308(Öйú)¹É·ÝÓÐÏÞ¹«Ë¾  Î¬¶àÀûÑÇÀÏÆ·ÅÆvic3308(Öйú)¹É·ÝÓÐÏÞ¹«Ë¾  Î¬¶àÀûÑÇÀÏÆ·ÅÆvic3308(Öйú)¹É·ÝÓÐÏÞ¹«Ë¾  Î¬¶àÀûÑÇÀÏÆ·ÅÆvic3308(Öйú)¹É·ÝÓÐÏÞ¹«Ë¾

·µ»ØÁбí <
ά¶àÀûÑÇÀÏÆ·ÅÆvic3308(Öйú)¹É·ÝÓÐÏÞ¹«Ë¾
ÔÚÏßÁôÑÔ

ллÄú¶ÔÕÑÑܵĹØ×¢¡£¡£¡£ ¡£¡£ÇëÌîдÏÂÃæµÄÐÅÏ¢£¬£¬£¬£¬£¬£¬£¬ÎÒÃÇ»áʵʱÓëÄúÁªÏµ¡£¡£¡£ ¡£¡£

ÑéÖ¤Âë
¡¾ÍøÕ¾µØÍ¼¡¿¡¾sitemap¡¿